Work

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?

Year: 2011

Type: article

Abstract: β-Secretase is an attractive target of amyloid-reduction therapy for Alzheimer's disease. Currently, no efficacy data is available from clinical trials of β-secretase inhibitors. Treating young transgenic Tg2576 mice with a brain-penetrating β-secretase inhibitor reduced brain amyloid-β by about 50% and rescued the age-related cognitive decline. Implications from these model studies on the design of clinical trials are discussed herein.

Source: Aging

DOI: 10.18632/aging.100267

Authors: Jordan Tang, Arun Ghosh

Institutions: Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, University of Oklahoma, Purdue University West Lafayette

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of General Medical Sciences